IMCLONE SYSTEMS INC/DE
424B3, 2000-09-15
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CATERPILLAR FINANCIAL SERVICES CORP, 424B2, 2000-09-15
Next: ADVANTUS SERIES FUND INC, NSAR-A/A, 2000-09-15





PROSPECTUS SUPPLEMENT                           FILED PURSUANT TO RULE 424(B)(3)
TO PROSPECTUS DATED JULY 31, 2000                     REGISTRATION NO. 333-37746

                                  $240,000,000

                          IMCLONE SYSTEMS INCORPORATED

                 5 1/2% Convertible Subordinated Notes Due 2005

     This prospectus supplement relates to the resale by the holders of our 5
1/2% Convertible Subordinated Notes Due 2005 and the shares of our common stock
issuable upon the conversion of the notes.

     This prospectus supplement should be read in conjunction with the
prospectus dated July 31, 2000, which is to be delivered with this prospectus
supplement. All capitalized terms used but not defined in the prospectus
supplement shall have the meanings given to them in the prospectus.

     The table below sets forth information as of the date hereof concerning
beneficial ownership of the securities of the selling holders as listed below.
All information concerning beneficial ownership has been furnished by the
selling holders.

                              PRINCIPAL AMOUNT     COMMON STOCK
                                  OF NOTES          OWNED PRIOR     COMMON STOCK
                             BENEFICIALLY OWNED        TO THE          OFFERED
NAME                         AND OFFERED HEREBY   OFFERINGS(1)(2)   HEREBY(1)(2)
---------------------------  ------------------   ---------------   ------------
Merrill Lynch Pierce
Fenner & Smith, Inc.              1,100,000             9,983            9,983

R2 Investments, LDC              22,750,000           206,480          206,480
---------
(1) Assumes a conversion price of $110.18 per share and a cash payment in lieu
   of any fractional interest.

(2)  Assumes that any holders of notes or any future transferee from any such
     holder does not beneficially own any common stock other than common stock
     into which the notes are convertible at the conversion price of $110.18
     per share.

Other than as may be stated in any additional prospectus supplement, none of
the selling holders has had any material relationship with us or with our
affiliates within the past three years.

                            -----------------------

The securities offered hereby involve a high degree of risk. See "Risk Factors"
                    beginning on page 4 of the prospectus.

         These securities have not been approved or disapproved by the
    Securities and Exchange Commission nor has the Securities and Exchange
   Commission or any State Securities Commission passed upon the accuracy or
     adequacy of this prospectus. Any representation to the contrary is a
                               criminal offense.

                            -----------------------

         The date of this prospectus supplement is September 15, 2000.


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission